DCOY · Decoy Therapeutics Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern. Based on Decoy's expected cash requirements, Decoy believes that there is substantial doubt that its existing cash and cash equivalents, will be sufficient to fund its operations through one year from the financial statements' issuance date.”View the 10-Q filed May 8, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | — | — | — | $0 | $1.84M | $5.23M | $3.47M | $1.95M | $1.27M | $1.01M | $0 | — | |
| $250.35K | — | — | — | — | — | — | — | $430.75K | $506.53K | $662.75K | $0 | — | |
| $1.93M | — | — | — | — | — | — | — | $1.52M | $767.97K | $347.92K | $0 | — | |
| — | — | — | — | — | — | — | — | 77.93% | 60.26% | 34.42% | — | — | |
| $1.04M | $368.17K | $770.03K | $7.17M | $15.84M | $8.55M | $6.91M | $4.02M | $1.29M | $16.99M | $20.38M | $12.75M | $4M | |
| $3.62M | $3.73M | $4.96M | $5.72M | $7.14M | $6.1M | $6.11M | $7.71M | $2.35M | $18.5M | $19.86M | $16.46M | $4.03M | |
| — | $7151 | $4424 | $10.05K | $6677 | $19.18K | $18.06K | $127.41K | $16.95K | — | — | — | — | |
| — | — | — | — | — | — | — | — | $1.37M | — | — | — | — | |
| $13.18M | $12.61M | $5.73M | $12.89M | $31.84M | $14.65M | $13.02M | $11.73M | $3.64M | $36M | $40.9M | $29.21M | $8.03M | |
| -$13.18M | -$12.61M | -$5.73M | -$12.89M | -$31.84M | -$12.81M | -$7.79M | -$8.27M | -$1.68M | -$34.73M | -$39.89M | -$29.21M | — | |
| — | — | — | — | — | -696.27% | -148.78% | -238.53% | -86.33% | -2724.65% | -3946.54% | — | — | |
| — | -$12.61M | -$5.73M | -$12.88M | -$31.83M | -$12.79M | -$7.77M | -$8.14M | -$1.67M | — | — | — | — | |
| -$39.89M | — | — | — | — | — | — | — | — | — | — | -$29.21M | -$8.03M | |
| — | $0 | — | — | — | — | — | $0 | — | — | — | — | — | |
| $12M | $12.52M | $5.58M | $12.54M | -$31.61M | -$12.77M | -$7.35M | -$6.94M | -$1.67M | -$34.43M | -$39.49M | -$29.14M | -$8.01M | |
| — | — | — | — | — | -693.84% | -140.49% | -200.18% | -85.56% | -2701.74% | -3907.65% | — | — | |
| — | — | -$5.58M | -$12.54M | -$31.61M | -$12.77M | -$7.75M | -$6.94M | -$21.92M | -$34.43M | -$39.49M | -$29.14M | -$8.01M | |
| -$8.26M | — | — | — | — | — | — | — | -$21.92M | -$34.43M | -$39.47M | -$29.17M | -$8.01M | |
| USD/shares | — | -$129.10 | -$69.54 | -$5,533.20 | -$21,427.20 | -$11,116.80 | -$18,000.00 | — | — | — | — | — | — |
| USD/shares | — | -$129.10 | -$69.54 | -$5,533.20 | -$21,427.20 | -$11,116.80 | -$18,000.00 | — | — | — | — | — | — |
| shares | — | 96.97K | 80.18K | 2267.1 | 1475.3549 | 1149.0542 | 432.7392 | 90.7955 | 42.7608 | 479.4618 | 450.944 | 389.8032 | 48.6951 |
| shares | — | 96.97K | 80.18K | 2267.1 | 1475.3549 | 1149.0542 | 432.7392 | 90.7955 | 42.7608 | 479.4618 | 450.944 | 389.8032 | 48.6951 |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2020: $133.59K in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 118 similar-size Biotechnology companies (of 522 listed).
Valuation over time computed as of each quarter's filing date
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$12,613,952 | -$5,734,316 | — |
| Reportable Segment | — | — | -$12,894,944 |